Retinoblastom;Retinoblastoma

Ophthalmologe

Volumn 103, Issue 1, 2006, Pages 59-78

  Bornfeld, N ^a   Schuler A ^a   Boloni R ^a   Jurklies, C ^a   Wieland, R ^a   Sauerwein, W ^a   Lohmann, D ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Differential diagnosis; Eye salvaging therapy; Hereditary retinoblastoma; Non hereditary retinoblastoma; Systemic therapy

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; GANCICLOVIR; RETINOBLASTOMA PROTEIN; THYMIDINE KINASE;

BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL RESEARCH; CRYOTHERAPY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; ENUCLEATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MOLECULAR GENETICS; PATHOPHYSIOLOGY; RETINOBLASTOMA; REVIEW; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; CLINICAL PRACTICE; EYE TUMOR; GENETICS; MORTALITY; PRACTICE GUIDELINE;

DIAGNOSIS, DIFFERENTIAL; EYE NEOPLASMS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RETINOBLASTOMA;

EID: 31644450880     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-005-1296-1     Document Type: Review

References (39)

1. Aartsma-Rus A, Janson AA, Kaman WE et al. (2004) Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet 74:83-92
2. Abramson DH, Marks RF, Ellsworth RM et al. (1982) The management of unilateral retinoblastoma without primary enucleation. Arch Ophthalmol 100:1249-1252
3. Abramson DH, Gamell LS, Ellsworth RM et al. (1994) Unilateral retinoblastoma: new intraocular tumours after treatment. Br J Ophthalmol 78:698-701
4. Abramson DH, Frank CM (1998) Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology 105:573-579
5. Abramson DH, Schefler AC (2004) Update on retinoblastoma. Retina 24:828-848
6. Bechrakis NE, Bornfeld N, Schüler A et al. (1998) Clinicopathologic features of retinoblastoma after primary chemoreduction. Arch Ophthalmol 116:887-893
7. Bornfeld N, Schüler A, Bechrakis N et al. (1997) Preliminary results of primary chemotherapy in retinoblastoma. Klin Padiatr 209:216-221
8. Chevez-Barrios P, Chintagumpala M, Mieler W et al. (2005) Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J Clin Oncol 23:7927-7935
9. De Potter P, Shields CL, Shields JA (1994) Clinical variations of trilateral retinoblastoma: a report of 13 cases. J Pediatr Ophthalmol Strabismus 31:26-31
10. Eng C, Li FP, Abramson DH et al. (1993) Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 85:1121-1128
11. Gallie BL, Budning A, DeBoer G et al. (1996) Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 114:1321-1328
12. Genuardi M, Klutz M, Devriendt K et al. (2001) Multiple lipomas linked to an RB1 gene mutation in a large pedigree with low penetrance retinoblastoma. Eur J Hum Genet 9:690-694
13. Gombos DS, Kelly A, Coen PG et al. (2002) Retinoblastoma treated with primary chemotherapy alone: the significance of tumour size, location, and age. Br J Ophthalmol 86:80-83
14. Karcioglu ZA (2002) Fine needle aspiration biopsy (FNAB) for retinoblastoma. Retina 22:707-710
15. Kivelä T (1999) Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol 17:1829-1837
16. Kremens B, Wieland R, Reinhard H et al. (2003) High-dose chemotherapy with autologous stem cell rescue in children with retinoblastoma. Bone Marrow Transplant 31:281-284
17. Laurie NA, Gray JK, Zhang J et al. (2005) Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin Cancer Res 11:7569-7578
18. Lidegaard O, Pinborg A, Andersen AN (2005) Imprinting diseases and IVF: Danish National IVF cohort study. Hum Reprod 20:950-954
19. Lohmann DR, Gerick M, Brandt B et al. (1997) Constitutional RB1-gene mutations in patients with isolated unilateral retinoblastoma. Am J Hum Genet 61:282-294
20. Lohmann DR (1999) RB1 gene mutations in retinoblastoma. Hum Mutat 14:283-288
21. Lohmann DR, Gallie BL (2004) Retinoblastoma: revisiting the model prototype of inherited cancer. Am J Med Genet C Semin Med Genet 129:23-28
22. Moll AC, Imhof SM, Schouten-Van Meeteren AY et al. (2001) Second primary tumors in hereditary retinoblastoma: a register-based study, 1945-1997: is there an age effect on radiation-related risk? Ophthalmology 108:1109-1114
23. Moll AC, Imhof SM, Schouten-van Meeteren AY et al. (2003) In-vitro fertilisation and retinoblastoma. Lancet 361:1392
24. Mulvihill A, Budning A, Jay V et al. (2003) Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol 121:1120-1124
25. Murphree AL, Villablanca JG, Deegan WF et al. (1996) Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 114:1348-1356
26. Murphree AL (2005) Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am 18:41-53, viii
27. Niemitz EL, Feinberg AP (2004) Epigenetics and assisted reproductive technology: a call for investigation. Am J Hum Genet 74:599-609
28. Noorani HZ, Khan HN, Gallie BL et al. (1996) Cost comparison of molecular versus conventional screening of relatives at risk for retinoblastoma. Am J Hum Genet 59:301-307
29. Schüler A, Weber S, Neuhauser M et al. (2005) Age at diagnosis of isolated unilateral retinoblastoma does not distinguish patients with and without a constitutional RB1 gene mutation but is influenced by a parent-of-origin effect. Eur J Cancer 41:735-740
30. Schüler AO, Bornfeld N (2000) Aktuelle Therapieaspekte intraokularer Tumoren. Ophthalmologe 97:207-222
31. Schüler AO, Jurklies C, Heimann H et al. (2003) Thermochemotherapy in hereditary retinoblastoma. Br J Ophthalmol 87:90-95
32. Shields CL, De Potter P, Himelstein BP et al. (1996) Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol 114:1330-1338
33. Shields CL, Shields JA, De Potter P (1996) New treatment modalities for retinoblastoma. Curr Opin Ophthalmol 7:20-26
34. Shields CL, Meadows AT, Shields JA et al. (2001) Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma). Arch Ophthalmol 119:1269-1272
35. Shields JA, Shields CL, Meadows AT (2005) Chemoreduction in the management of retinoblastoma. Am J Ophthalmol 140:505-506
36. Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792
37. Toma NM, Hungerford JL, Plowman PN et al. (1995) External beam radiotherapy for retinoblastoma: II. Lens sparing technique. Br J Ophthalmol 79:112-117
38. White L (1991) Chemotherapy for retinoblastoma: where do we go from here? A review of published literature and meeting abstracts, including discussions during the Vth International Symposium on Retinoblastoma, October 1990. Ophthalmic Paediatr Genet 12:115-130
39. Wieland R, Lohmann D, Schüler A et al. (2004) Retinoblastom. In: Hiddemann W, Huber H, Bartram C (Hrsg) Die Onkologie. Springer, Berlin Heidelberg New YorkTokyo, S 1698-1707